Fortrea Holdings Inc.
FTRE
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.7B
$17.70
▼ -4.94%
P/E
-19.24
Mkt Cap
$1.7B
52-Wk Range
$8.31–$21.39
52-Week Range
$8.31 - $21.39
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 71.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Integrated two-segment model combining clinical expertise with proprietary technology solutions
- Flexible delivery models (full service, FSP, hybrid) enabling customized client partnerships
- Technology-enabled trial solutions that optimize patient recruitment, randomization, and drug supply efficiency
- Full-spectrum clinical development capabilities from Phase I through post-approval
- Scale and operational efficiency serving global pharmaceutical, biotech, and medical device markets
Bear Case
1 risk
- Above-average volatility (beta 2.0).
Growth
Turning profitable
Increasing pharmaceutical industry outsourcing of clinical trial management to specialized CROs
Value
Fairly valued vs Biotech & Therapeutics peers
Momentum
Strong
+6.8% over 3m
Quality
Thin
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying FTRE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
JUL 29, 2026
Reported EPS of $0.23 vs $0.18 consensus (+27.5% surprise). Revenue of $678.2M vs $647.6M expected (+4.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+27.5%
Revenue trend · last 8Q
—
-10%
-2%
+7%
+4%
-5%
-2%
-5%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$674.9M
$697.0M
$651.3M
$710.3M
$701.3M
$660.5M
$636.5M
$678.2M
Margins · last 8Q
Gross
-15.3%
Operating
1.2%
Profit
-1.9%
Wall Street consensus
6 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: TD Cowen · Aug 4, 2026
vs Industry
How FTRE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related